Overview

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Niacin
Niacinamide
Nicotinic Acids